The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Tumour-cell Vaccine Market Research Report 2025
Synopsis
Tumour-cell vaccines which contain tumour cells obtained from the patient following surgery are intended to prevent disease recurrence in patients who have received prior treatment.
The global Tumour-cell Vaccine market was valued at US$ 233 million in 2023 and is anticipated to reach US$ 345 million by 2030, witnessing a CAGR of 5.8% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Tumour-cell Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumour-cell Vaccine.
Report Scope
The Tumour-cell Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Tumour-cell Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tumour-cell Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AVAX Technologies
Vaccinogen
Biovest
Aduro BioTech
Regeneus
Segment by Type
MVax
OncoVAX
BiovaxID
Others
Segment by Application
Pediatrics
Adults
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Tumour-cell Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Tumour-cell Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Tumour-cell vaccines which contain tumour cells obtained from the patient following surgery are intended to prevent disease recurrence in patients who have received prior treatment.
The global Tumour-cell Vaccine market was valued at US$ 233 million in 2023 and is anticipated to reach US$ 345 million by 2030, witnessing a CAGR of 5.8% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Tumour-cell Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumour-cell Vaccine.
Report Scope
The Tumour-cell Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Tumour-cell Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tumour-cell Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AVAX Technologies
Vaccinogen
Biovest
Aduro BioTech
Regeneus
Segment by Type
MVax
OncoVAX
BiovaxID
Others
Segment by Application
Pediatrics
Adults
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Tumour-cell Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Tumour-cell Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Tumour-cell Vaccine Market Overview
1.1 Product Overview and Scope of Tumour-cell Vaccine
1.2 Tumour-cell Vaccine Segment by Type
1.2.1 Global Tumour-cell Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 MVax
1.2.3 OncoVAX
1.2.4 BiovaxID
1.2.5 Others
1.3 Tumour-cell Vaccine Segment by Application
1.3.1 Global Tumour-cell Vaccine Market Value by Application: (2024-2030)
1.3.2 Pediatrics
1.3.3 Adults
1.4 Global Tumour-cell Vaccine Market Size Estimates and Forecasts
1.4.1 Global Tumour-cell Vaccine Revenue 2019-2030
1.4.2 Global Tumour-cell Vaccine Sales 2019-2030
1.4.3 Global Tumour-cell Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Tumour-cell Vaccine Market Competition by Manufacturers
2.1 Global Tumour-cell Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Tumour-cell Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Tumour-cell Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Tumour-cell Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Tumour-cell Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Tumour-cell Vaccine, Product Type & Application
2.7 Tumour-cell Vaccine Market Competitive Situation and Trends
2.7.1 Tumour-cell Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Tumour-cell Vaccine Players Market Share by Revenue
2.7.3 Global Tumour-cell Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Tumour-cell Vaccine Retrospective Market Scenario by Region
3.1 Global Tumour-cell Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Tumour-cell Vaccine Global Tumour-cell Vaccine Sales by Region: 2019-2030
3.2.1 Global Tumour-cell Vaccine Sales by Region: 2019-2024
3.2.2 Global Tumour-cell Vaccine Sales by Region: 2025-2030
3.3 Global Tumour-cell Vaccine Global Tumour-cell Vaccine Revenue by Region: 2019-2030
3.3.1 Global Tumour-cell Vaccine Revenue by Region: 2019-2024
3.3.2 Global Tumour-cell Vaccine Revenue by Region: 2025-2030
3.4 North America Tumour-cell Vaccine Market Facts & Figures by Country
3.4.1 North America Tumour-cell Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Tumour-cell Vaccine Sales by Country (2019-2030)
3.4.3 North America Tumour-cell Vaccine Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Tumour-cell Vaccine Market Facts & Figures by Country
3.5.1 Europe Tumour-cell Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Tumour-cell Vaccine Sales by Country (2019-2030)
3.5.3 Europe Tumour-cell Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Tumour-cell Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Tumour-cell Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Tumour-cell Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Tumour-cell Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Tumour-cell Vaccine Market Facts & Figures by Country
3.7.1 Latin America Tumour-cell Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Tumour-cell Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Tumour-cell Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Tumour-cell Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Tumour-cell Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Tumour-cell Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Tumour-cell Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Tumour-cell Vaccine Sales by Type (2019-2030)
4.1.1 Global Tumour-cell Vaccine Sales by Type (2019-2024)
4.1.2 Global Tumour-cell Vaccine Sales by Type (2025-2030)
4.1.3 Global Tumour-cell Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Tumour-cell Vaccine Revenue by Type (2019-2030)
4.2.1 Global Tumour-cell Vaccine Revenue by Type (2019-2024)
4.2.2 Global Tumour-cell Vaccine Revenue by Type (2025-2030)
4.2.3 Global Tumour-cell Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Tumour-cell Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Tumour-cell Vaccine Sales by Application (2019-2030)
5.1.1 Global Tumour-cell Vaccine Sales by Application (2019-2024)
5.1.2 Global Tumour-cell Vaccine Sales by Application (2025-2030)
5.1.3 Global Tumour-cell Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Tumour-cell Vaccine Revenue by Application (2019-2030)
5.2.1 Global Tumour-cell Vaccine Revenue by Application (2019-2024)
5.2.2 Global Tumour-cell Vaccine Revenue by Application (2025-2030)
5.2.3 Global Tumour-cell Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Tumour-cell Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 AVAX Technologies
6.1.1 AVAX Technologies Corporation Information
6.1.2 AVAX Technologies Description and Business Overview
6.1.3 AVAX Technologies Tumour-cell Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 AVAX Technologies Tumour-cell Vaccine Product Portfolio
6.1.5 AVAX Technologies Recent Developments/Updates
6.2 Vaccinogen
6.2.1 Vaccinogen Corporation Information
6.2.2 Vaccinogen Description and Business Overview
6.2.3 Vaccinogen Tumour-cell Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Vaccinogen Tumour-cell Vaccine Product Portfolio
6.2.5 Vaccinogen Recent Developments/Updates
6.3 Biovest
6.3.1 Biovest Corporation Information
6.3.2 Biovest Description and Business Overview
6.3.3 Biovest Tumour-cell Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Biovest Tumour-cell Vaccine Product Portfolio
6.3.5 Biovest Recent Developments/Updates
6.4 Aduro BioTech
6.4.1 Aduro BioTech Corporation Information
6.4.2 Aduro BioTech Description and Business Overview
6.4.3 Aduro BioTech Tumour-cell Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Aduro BioTech Tumour-cell Vaccine Product Portfolio
6.4.5 Aduro BioTech Recent Developments/Updates
6.5 Regeneus
6.5.1 Regeneus Corporation Information
6.5.2 Regeneus Description and Business Overview
6.5.3 Regeneus Tumour-cell Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Regeneus Tumour-cell Vaccine Product Portfolio
6.5.5 Regeneus Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Tumour-cell Vaccine Industry Chain Analysis
7.2 Tumour-cell Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Tumour-cell Vaccine Production Mode & Process
7.4 Tumour-cell Vaccine Sales and Marketing
7.4.1 Tumour-cell Vaccine Sales Channels
7.4.2 Tumour-cell Vaccine Distributors
7.5 Tumour-cell Vaccine Customers
8 Tumour-cell Vaccine Market Dynamics
8.1 Tumour-cell Vaccine Industry Trends
8.2 Tumour-cell Vaccine Market Drivers
8.3 Tumour-cell Vaccine Market Challenges
8.4 Tumour-cell Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Tumour-cell Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Tumour-cell Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Tumour-cell Vaccine Market Competitive Situation by Manufacturers in 2023
Table 4. Global Tumour-cell Vaccine Sales (K Dose) of Key Manufacturers (2019-2024)
Table 5. Global Tumour-cell Vaccine Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Tumour-cell Vaccine Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Tumour-cell Vaccine Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Tumour-cell Vaccine Average Price (US$/Dose) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Tumour-cell Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Tumour-cell Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Tumour-cell Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Tumour-cell Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Tumour-cell Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumour-cell Vaccine as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Tumour-cell Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Tumour-cell Vaccine Sales by Region (2019-2024) & (K Dose)
Table 18. Global Tumour-cell Vaccine Sales Market Share by Region (2019-2024)
Table 19. Global Tumour-cell Vaccine Sales by Region (2025-2030) & (K Dose)
Table 20. Global Tumour-cell Vaccine Sales Market Share by Region (2025-2030)
Table 21. Global Tumour-cell Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Tumour-cell Vaccine Revenue Market Share by Region (2019-2024)
Table 23. Global Tumour-cell Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Tumour-cell Vaccine Revenue Market Share by Region (2025-2030)
Table 25. North America Tumour-cell Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Tumour-cell Vaccine Sales by Country (2019-2024) & (K Dose)
Table 27. North America Tumour-cell Vaccine Sales by Country (2025-2030) & (K Dose)
Table 28. North America Tumour-cell Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Tumour-cell Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Tumour-cell Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Tumour-cell Vaccine Sales by Country (2019-2024) & (K Dose)
Table 32. Europe Tumour-cell Vaccine Sales by Country (2025-2030) & (K Dose)
Table 33. Europe Tumour-cell Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Tumour-cell Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Tumour-cell Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Tumour-cell Vaccine Sales by Region (2019-2024) & (K Dose)
Table 37. Asia Pacific Tumour-cell Vaccine Sales by Region (2025-2030) & (K Dose)
Table 38. Asia Pacific Tumour-cell Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Tumour-cell Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Tumour-cell Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Tumour-cell Vaccine Sales by Country (2019-2024) & (K Dose)
Table 42. Latin America Tumour-cell Vaccine Sales by Country (2025-2030) & (K Dose)
Table 43. Latin America Tumour-cell Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Tumour-cell Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Tumour-cell Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Tumour-cell Vaccine Sales by Country (2019-2024) & (K Dose)
Table 47. Middle East & Africa Tumour-cell Vaccine Sales by Country (2025-2030) & (K Dose)
Table 48. Middle East & Africa Tumour-cell Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Tumour-cell Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Tumour-cell Vaccine Sales (K Dose) by Type (2019-2024)
Table 51. Global Tumour-cell Vaccine Sales (K Dose) by Type (2025-2030)
Table 52. Global Tumour-cell Vaccine Sales Market Share by Type (2019-2024)
Table 53. Global Tumour-cell Vaccine Sales Market Share by Type (2025-2030)
Table 54. Global Tumour-cell Vaccine Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Tumour-cell Vaccine Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Tumour-cell Vaccine Revenue Market Share by Type (2019-2024)
Table 57. Global Tumour-cell Vaccine Revenue Market Share by Type (2025-2030)
Table 58. Global Tumour-cell Vaccine Price (US$/Dose) by Type (2019-2024)
Table 59. Global Tumour-cell Vaccine Price (US$/Dose) by Type (2025-2030)
Table 60. Global Tumour-cell Vaccine Sales (K Dose) by Application (2019-2024)
Table 61. Global Tumour-cell Vaccine Sales (K Dose) by Application (2025-2030)
Table 62. Global Tumour-cell Vaccine Sales Market Share by Application (2019-2024)
Table 63. Global Tumour-cell Vaccine Sales Market Share by Application (2025-2030)
Table 64. Global Tumour-cell Vaccine Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Tumour-cell Vaccine Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Tumour-cell Vaccine Revenue Market Share by Application (2019-2024)
Table 67. Global Tumour-cell Vaccine Revenue Market Share by Application (2025-2030)
Table 68. Global Tumour-cell Vaccine Price (US$/Dose) by Application (2019-2024)
Table 69. Global Tumour-cell Vaccine Price (US$/Dose) by Application (2025-2030)
Table 70. AVAX Technologies Corporation Information
Table 71. AVAX Technologies Description and Business Overview
Table 72. AVAX Technologies Tumour-cell Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 73. AVAX Technologies Tumour-cell Vaccine Product
Table 74. AVAX Technologies Recent Developments/Updates
Table 75. Vaccinogen Corporation Information
Table 76. Vaccinogen Description and Business Overview
Table 77. Vaccinogen Tumour-cell Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 78. Vaccinogen Tumour-cell Vaccine Product
Table 79. Vaccinogen Recent Developments/Updates
Table 80. Biovest Corporation Information
Table 81. Biovest Description and Business Overview
Table 82. Biovest Tumour-cell Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 83. Biovest Tumour-cell Vaccine Product
Table 84. Biovest Recent Developments/Updates
Table 85. Aduro BioTech Corporation Information
Table 86. Aduro BioTech Description and Business Overview
Table 87. Aduro BioTech Tumour-cell Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 88. Aduro BioTech Tumour-cell Vaccine Product
Table 89. Aduro BioTech Recent Developments/Updates
Table 90. Regeneus Corporation Information
Table 91. Regeneus Description and Business Overview
Table 92. Regeneus Tumour-cell Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 93. Regeneus Tumour-cell Vaccine Product
Table 94. Regeneus Recent Developments/Updates
Table 95. Key Raw Materials Lists
Table 96. Raw Materials Key Suppliers Lists
Table 97. Tumour-cell Vaccine Distributors List
Table 98. Tumour-cell Vaccine Customers List
Table 99. Tumour-cell Vaccine Market Trends
Table 100. Tumour-cell Vaccine Market Drivers
Table 101. Tumour-cell Vaccine Market Challenges
Table 102. Tumour-cell Vaccine Market Restraints
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Tumour-cell Vaccine
Figure 2. Global Tumour-cell Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Tumour-cell Vaccine Market Share by Type in 2023 & 2030
Figure 4. MVax Product Picture
Figure 5. OncoVAX Product Picture
Figure 6. BiovaxID Product Picture
Figure 7. Others Product Picture
Figure 8. Global Tumour-cell Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Tumour-cell Vaccine Market Share by Application in 2023 & 2030
Figure 10. Pediatrics
Figure 11. Adults
Figure 12. Global Tumour-cell Vaccine Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Tumour-cell Vaccine Market Size (2019-2030) & (US$ Million)
Figure 14. Global Tumour-cell Vaccine Sales (2019-2030) & (K Dose)
Figure 15. Global Tumour-cell Vaccine Average Price (US$/Dose) & (2019-2030)
Figure 16. Tumour-cell Vaccine Report Years Considered
Figure 17. Tumour-cell Vaccine Sales Share by Manufacturers in 2023
Figure 18. Global Tumour-cell Vaccine Revenue Share by Manufacturers in 2023
Figure 19. The Global 5 and 10 Largest Tumour-cell Vaccine Players: Market Share by Revenue in 2023
Figure 20. Tumour-cell Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 21. Global Tumour-cell Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 22. North America Tumour-cell Vaccine Sales Market Share by Country (2019-2030)
Figure 23. North America Tumour-cell Vaccine Revenue Market Share by Country (2019-2030)
Figure 24. United States Tumour-cell Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Canada Tumour-cell Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Europe Tumour-cell Vaccine Sales Market Share by Country (2019-2030)
Figure 27. Europe Tumour-cell Vaccine Revenue Market Share by Country (2019-2030)
Figure 28. Germany Tumour-cell Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. France Tumour-cell Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. U.K. Tumour-cell Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Italy Tumour-cell Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Russia Tumour-cell Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Asia Pacific Tumour-cell Vaccine Sales Market Share by Region (2019-2030)
Figure 34. Asia Pacific Tumour-cell Vaccine Revenue Market Share by Region (2019-2030)
Figure 35. China Tumour-cell Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Japan Tumour-cell Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. South Korea Tumour-cell Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. India Tumour-cell Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Australia Tumour-cell Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. China Taiwan Tumour-cell Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Indonesia Tumour-cell Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Thailand Tumour-cell Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Malaysia Tumour-cell Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Latin America Tumour-cell Vaccine Sales Market Share by Country (2019-2030)
Figure 45. Latin America Tumour-cell Vaccine Revenue Market Share by Country (2019-2030)
Figure 46. Mexico Tumour-cell Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Brazil Tumour-cell Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Argentina Tumour-cell Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa Tumour-cell Vaccine Sales Market Share by Country (2019-2030)
Figure 50. Middle East & Africa Tumour-cell Vaccine Revenue Market Share by Country (2019-2030)
Figure 51. Turkey Tumour-cell Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Saudi Arabia Tumour-cell Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. UAE Tumour-cell Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Global Sales Market Share of Tumour-cell Vaccine by Type (2019-2030)
Figure 55. Global Revenue Market Share of Tumour-cell Vaccine by Type (2019-2030)
Figure 56. Global Tumour-cell Vaccine Price (US$/Dose) by Type (2019-2030)
Figure 57. Global Sales Market Share of Tumour-cell Vaccine by Application (2019-2030)
Figure 58. Global Revenue Market Share of Tumour-cell Vaccine by Application (2019-2030)
Figure 59. Global Tumour-cell Vaccine Price (US$/Dose) by Application (2019-2030)
Figure 60. Tumour-cell Vaccine Value Chain
Figure 61. Tumour-cell Vaccine Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
